Evotec SE (EVO), a drug manufacturing company, Wednesday announced that its partner Zhejiang Jingxin Pharmaceutical Co., Ltd has received approval for EVT201 in China for short-term treatment of insomnia.Insomnia is the difficulty in falling or staying asleep, and is seen in roughly 10-20% of general population, especially in women, elderly and people with comorbid medical and psychiatric conditions.Evotec granted exclusive rights to Zhejiang JingXin Pharma to develop and market EVT201 in China, under an agreement signed in October 2010..

药物制造公司Evotec SE（EVO）周三宣布，其合作伙伴浙江晶鑫制药有限公司已获得中国EVT201短期治疗失眠的批准。失眠是入睡或保持睡眠的困难，大约占总人口的10-20%，尤其是女性，老年人以及患有合并症和精神病的人。根据2010年10月签署的协议，Evotec授予浙江精信制药在中国开发和销售EVT201的独家权利。。

Now that EVT201 has been approved in China, Evotec expects to receive double-digit royalties of net sales as well as milestones based on commercial success and further sub-licensing.On Tuesday, Evotec's shares closed at $9.82, falling by 0.10%. For comments and feedback contact: editorial@rttnews.comBusiness News.

既然EVT201已在中国获得批准，Evotec预计将获得两位数的净销售额版税，以及基于商业成功和进一步分许可的里程碑。周二，Evotec股价收于9.82美元，下跌0.10%。有关评论和反馈，请联系：editorial@rttnews.combusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股